Center Laboratories Inc.

Established in 1959, Center Laboratories Inc. rapidly gained an excellent reputation in the industry for developing diverse medical solutions. After decades of innovation and transformation, it was repositioned in 1998 as a professional oral liquid pharmaceutical company offering solutions for the medication needs of infants, children, the elderly and special care patients. Center Laboratories continues to develop diverse oral medical solutions and has been widely recognized by the industry and consumers. In the future, it strives to become Asia’s most professional oral liquid pharmaceutical company, leader in CNS field, and expert in cross-strait specialty drug development.

CS02, a specialty drug candidate of CenterLab, is an anti-diabetic drug based on new MOA. CS02 got approval of Phase II trial from USFDA and TWFDA in 2017 and completed in 2020. CS02 met its primary endpoint and showed significant decreases of HbA1c in treated patients as compared to placebo group by 0.45% (p value = 0.0098 ). HOMA2-β, one of secondary endpoints, was increased by 13.45%.